• Members of the Kuhns Lab study the "conversations" between T cells and the rest of the immune system.

    From the Bench to the Bedside

    To Develop New Immunotherapies, Collaboration Is Key

  • Hani Babiker, MD, and patient

    Too Much of a Good Thing: Managing Immunotherapy Side Effects

    Immunotherapy can backfire when a supercharged immune system attacks healthy cells, but researchers are hopeful for the future.

  • Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

    Pancreatic Cancer Patients with BRCA Mutation May Benefit from Targeted Drug

    Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

Members of the Kuhns Lab study the "conversations" between T cells and the rest of the immune system.
Hani Babiker, MD, and patient
Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.
Members of the Kuhns Lab study the "conversations" between T cells and the rest of the immune system.

From the Bench to the Bedside

To Develop New Immunotherapies, Collaboration Is Key

Hani Babiker, MD, and patient

Too Much of a Good Thing: Managing Immunotherapy Side Effects

Immunotherapy can backfire when a supercharged immune system attacks healthy cells, but researchers are hopeful for the future.

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

Pancreatic Cancer Patients with BRCA Mutation May Benefit from Targeted Drug

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.

News Stories

To Develop New Immunotherapies, Collaboration Is Key

Immunotherapy can backfire when a supercharged immune system attacks healthy cells, but researchers are hopeful for the future.

Rachna Shroff, MD, led a landmark study on the use of targeted drugs called PARP inhibitors in pancreatic cancer patients with BRCA mutations.